US 12,005,083 B1
Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
Michael Bernard Miklus, Essex Junction, VT (US); Anja Monika Wittke, Munich (DE); Pedro Antonio Prieto, Columbus, OH (US); and Cynthia M. Barber, Gordonsville, VA (US)
Assigned to PBM Nutritionals, LLC, Allegan, MI (US)
Filed by PBM Nutritionals, LLC, Allegan, MI (US)
Filed on Jun. 24, 2020, as Appl. No. 16/910,849.
Claims priority of provisional application 62/865,879, filed on Jun. 24, 2019.
Int. Cl. A61K 31/661 (2006.01); A23L 2/66 (2006.01); A23L 33/00 (2016.01); A23L 33/12 (2016.01); A23L 33/125 (2016.01); A23L 33/15 (2016.01); A23L 33/19 (2016.01); A61K 9/00 (2006.01); A61K 31/202 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 35/20 (2006.01)
CPC A61K 35/20 (2013.01) [A23L 2/66 (2013.01); A23L 33/12 (2016.08); A23L 33/125 (2016.08); A23L 33/15 (2016.08); A23L 33/19 (2016.08); A23L 33/40 (2016.08); A61K 9/0056 (2013.01); A61K 9/0095 (2013.01); A61K 31/202 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/661 (2013.01); A23V 2002/00 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method for supporting cognitive function and/or neuron cellular health in an individual in need thereof, comprising the step of administering to the individual a therapeutically effective amount of a nutritional composition,
wherein the nutritional composition comprises a milk fat globule membrane component, at least one human milk oligosaccharide, and docosahexaenoic acid (DHA),
wherein the DHA is converted to a phospholipid form of the DHA in the gastrointestinal tract of the individual, and
wherein the level of the phospholipid form of the DHA in the blood of the individual is increased following said administering as compared to blood of an individual administered an otherwise identical nutritional composition not comprising said at least one human milk oligosaccharide.